Article Text

Download PDFPDF
Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors SD-B and YY participated in writing the paper, drafted the word and approved the final version to be published.

  • Competing interests SD-B has received research grants from Roche, Janssen and Schering-Plough/Merck, and consultancy honoraria from Abbott, Abbvie, Bristol-Myers Squibb, Glaxo Smith Kline, HEVA, Janssen, Schering-Plough/Merck and Public Health Expertise. YY has received travel grants, lecture fees and consulting honoraria from Abbott/Abbvie, Bristol-Myers Squibb Gilead, Roche, Schering-Plough/Merck, Tibotec and ViiV Healthcare.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles